DrugPatentWatch Database Preview
ERGOMAR Drug Profile
» See Plans and Pricing
When do Ergomar patents expire, and when can generic versions of Ergomar launch?
Ergomar is a drug marketed by Tersera Theraps Llc and is included in one NDA.
The generic ingredient in ERGOMAR is ergotamine tartrate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ergotamine tartrate profile page.
Summary for ERGOMAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 12 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,999 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ERGOMAR at DailyMed |
Recent Clinical Trials for ERGOMAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stanford University | Phase 2 |
Pharmacology for ERGOMAR
| Drug Class | Ergotamine Derivative |
US Patents and Regulatory Information for ERGOMAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tersera Theraps Llc | ERGOMAR | ergotamine tartrate | TABLET;SUBLINGUAL | 087693-001 | Feb 24, 1983 | RX | No | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
